Antimicrobial Resistance Spectrum Conferred by pRErm46 of Emerging Macrolide (Multidrug)-Resistant Rhodococcus equi-Reference-Cited by-同舟云学术

Antimicrobial Resistance Spectrum Conferred by pRErm46 of Emerging Macrolide (Multidrug)-Resistant Rhodococcus equi

Published:2021-09-20 Issue:10 Volume:59 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Erol Erdal¹,Scortti Mariela²,Fortner Jordan¹,Patel Mukesh¹,Vázquez-Boland José A.²^ORCID

Affiliation:

1. Veterinary Diagnostic Laboratory, University of Kentucky, Lexington, Kentucky, USA

2. Microbial Pathogenesis Laboratory, Infection Medicine, Edinburgh Medical School (Biomedical Sciences), University of Edinburgh, Edinburgh, United Kingdom

Abstract

Clonal multidrug resistance recently emerged in Rhodococcus equi , complicating the therapeutic management of this difficult-to-treat animal- and human-pathogenic actinomycete. The currently spreading multidrug-resistant (MDR) “2287” clone arose in equine farms upon acquisition, and coselection by mass macrolide-rifampin therapy, of the pRErm46 plasmid carrying the erm (46) macrolide-lincosamide-streptogramin resistance determinant and of an rpoB S531F mutation.

Funder

Horserace Betting Levy Board

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.01149-21

Reference80 articles.

1. Rhodococcus equi: an animal and human pathogen

2. Rhodococcus equi:An Emerging Pathogen

3. Rhodococcus equi: The many facets of a pathogenic actinomycete